B. Riley Reiterates “$6.00” Price Target for Biomerica (NASDAQ:BMRA)

B. Riley set a $6.00 price objective on Biomerica (NASDAQ:BMRA) in a report issued on Tuesday, TipRanks reports. The firm currently has a buy rating on the stock. B. Riley also issued estimates for Biomerica’s Q1 2020 earnings at ($0.06) EPS, Q2 2020 earnings at ($0.08) EPS, Q3 2020 earnings at ($0.06) EPS, FY2020 earnings at ($0.27) EPS and FY2022 earnings at $0.75 EPS.

Shares of NASDAQ:BMRA traded up $0.18 during mid-day trading on Tuesday, hitting $3.05. The stock had a trading volume of 24,500 shares, compared to its average volume of 27,625. The company has a market cap of $28.91 million, a PE ratio of -11.73 and a beta of 1.45. Biomerica has a 12-month low of $1.60 and a 12-month high of $3.78. The company’s 50 day moving average is $3.13 and its 200-day moving average is $2.67.

Biomerica (NASDAQ:BMRA) last issued its quarterly earnings results on Friday, August 30th. The company reported ($0.08) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.08). The business had revenue of $1.17 million during the quarter, compared to the consensus estimate of $1.36 million. Biomerica had a negative net margin of 46.01% and a negative return on equity of 58.31%. As a group, equities research analysts anticipate that Biomerica will post -0.33 EPS for the current fiscal year.

An institutional investor recently bought a new position in Biomerica stock. Susquehanna International Group LLP purchased a new stake in Biomerica, Inc. (NASDAQ:BMRA) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 17,688 shares of the company’s stock, valued at approximately $46,000. Susquehanna International Group LLP owned approximately 0.18% of Biomerica as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 1.24% of the company’s stock.

Biomerica Company Profile

Biomerica, Inc, together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions. The company's diagnostic test kits are used to analyze blood, urine, or fecal samples from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific hormones, antibodies, antigens, or other substances, which exist in the human body in extremely small concentrations.

Featured Article: Margin

Receive News & Ratings for Biomerica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomerica and related companies with MarketBeat.com's FREE daily email newsletter.